机译:索拉非尼联合替西罗莫司治疗复发性胶质母细胞瘤或青光眼肉瘤的I / II期研究:北美脑肿瘤联盟研究05-02
Center for Neuro-Oncology, Dana Farber/Brigham and Women's Cancer Center, Boston, Massachusetts;
University of Texas Health Science Center, San Antonio, Texas;
Department of Neurosurgery, University of California, San Francisco, California;
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York;
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York;
University of Wisconsin, Madison, WI;
Department of Neurosurgery, University of California, San Francisco, California;
University of Texas MD Anderson Cancer Center, Houston, Texas;
Center for Neuro-Oncology, Dana Farber/Brigham and Women's Cancer Center, Boston, Massachusetts,Department of Neurology, University of Pittsburgh, Pennsylvania;
Northwestern University, Chicago Illinois;
University of Texas MD Anderson Cancer Center, Houston, Texas;
University of Texas MD Anderson Cancer Center, Houston, Texas;
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland;
Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland;
Department of Neurosurgery, University of California, San Francisco, California;
Department of Neurology, UCLA School of Medicine, University of California, Los Angeles, California;
University of Texas MD Anderson Cancer Center, Houston, Texas;
Center for Neuro-Oncology, Dana Farber/Brigham and Women's Cancer Center, 450 Brookline Avenue, SW 430, Boston, MA 02215;
anaplastic glioma; glioblastoma; malignant glioma; sorafenib; temsirolimus;
机译:厄洛替尼和西罗莫司治疗复发性恶性神经胶质瘤的Ⅰ/Ⅱ期研究:北美脑肿瘤联合试验04-02
机译:阿柏西普在复发性恶性神经胶质瘤中的II期研究:一项北美脑肿瘤联合研究。
机译:甲磺酸伊马替尼用于复发性脑膜瘤的II期研究(北美脑肿瘤联盟研究01-08)
机译:光敏疗法治疗恶性脑肿瘤的临床研究:Photofrin-PDT治疗复发性胶质瘤患者的卡氏评分和神经系统评分
机译:长春新碱,伊非替康,替莫唑胺和贝伐单抗(VIT-B)逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
机译:索拉非尼联合替西罗莫司治疗复发性胶质母细胞瘤或青光眼肉瘤的I / II期研究:北美脑肿瘤联盟研究05-02
机译:索拉非尼与紫外线血管瘤或胶质瘤的阶段I / II类研究:北美脑肿瘤联盟研究05-02